Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

Neurology
Ludwig KapposGordon Francis

Abstract

To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS). Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study, continuing fingolimod 0.5 mg/day or 1.25 mg/day, or switching from placebo to either dose, randomized 1:1. Efficacy variables included annualized relapse rate (ARR), brain volume loss (BVL), and confirmed disability progression (CDP). Between-group analyses were conducted in the intent-to-treat (ITT) population from FREEDOMS baseline to end of study. Within-group analyses compared years 0-2 (FREEDOMS) and years 2-4 (extension) in the extension ITT population. Of 1,272 patients (FREEDOMS ITT population), 1,033 were eligible, and 920 enrolled in the extension study (continuous-fingolimod: 0.5 mg [n = 331], 1.25 mg [n = 289]; placebo-fingolimod: 0.5 mg [n = 155], 1.25 mg [n = 145]); 916 formed the extension ITT population (n = 330; n = 287; n = 154; n = 145) and 773 (84%) completed. In the continuous-fingolimod groups, ARR was lower (p < 0.0001), BVL was reduced (p < 0.05), and proportionately more patients were free from 3-month CDP (p < 0.05) than in a ...Continue Reading

Citations

Sep 24, 2015·Annual Review of Medicine·Rebecca Straus FarberFred Lublin
Oct 27, 2015·Biological Chemistry·Paola SignorelliAnna Caretti
Dec 26, 2015·Journal of Neurology·Tjalf ZiemssenSven Schippling
Mar 6, 2016·Current Neurology and Neuroscience Reports·Benedikt KretzschmarMartin S Weber
Sep 28, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Felicity AllenNicholas Adlard
Sep 10, 2015·Mayo Clinic Proceedings·Margherita RussoRocco Salvatore Calabrò
Apr 30, 2015·Current Opinion in Neurology·Jiwon Oh, Paul W O'Connor
Jul 28, 2016·Multiple Sclerosis and Related Disorders·Axel Meissner, Volker Limmroth
Jun 27, 2015·Journal of Neurology, Neurosurgery, and Psychiatry·Jeffrey A CohenUNKNOWN TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group
Jun 9, 2016·Current Neurology and Neuroscience Reports·I-Jun ChouCris S Constantinescu
Sep 20, 2016·Multiple Sclerosis and Related Disorders·Gavin GiovannoniTimothy Vollmer
Jul 15, 2016·Expert Opinion on Biological Therapy·Sirin GandhiRobert Zivadinov
Sep 7, 2016·Expert Opinion on Pharmacotherapy·Nikolaos GrigoriadisGünther F L Hofbauer
Oct 21, 2016·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Alice LaroniGiovanni Luigi Mancardi
Oct 22, 2016·Expert Review of Neurotherapeutics·Catalina CoclituRadu Tanasescu
Dec 17, 2016·International Journal of Molecular Sciences·Refik PulThomas Skripuletz
May 22, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Despoina PapathemeliJens Ulrich
May 22, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Ralf GoldTheodore J Phillips
Jul 15, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Maria Pia SormaniNicola De Stefano
Mar 19, 2016·PloS One·Tobias Djamsched FaizySusanne Siemonsen
May 4, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Anne FroehlichJoerg Wenzel
Apr 20, 2016·The Cochrane Database of Systematic Reviews·Loredana La MantiaGraziella Filippini
Jun 12, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Morten RiemenschneiderUlrik Dalgas
Nov 9, 2018·Expert Opinion on Pharmacotherapy·Ludwig Rasche, Friedemann Paul
Jan 10, 2019·Annual Review of Pharmacology and Toxicology·Jerold ChunVictoria A Blaho
Feb 15, 2019·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M BoremalmJ Salzer
Jan 23, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Xavier MontalbanFrauke Zipp
Jan 21, 2018·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·X MontalbanF Zipp
Nov 2, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Jeremy HobartGavin Giovannoni
Aug 25, 2017·Neurology·Alasdair J ColesUNKNOWN CARE-MS II and CAMMS03409 Investigators
Mar 19, 2019·Neurology. Neuroimmunology and Neuroinflammation·Tjalf ZiemssenUNKNOWN PANGAEA study group
Feb 15, 2020·Annals of Neurology·Peter AlpingThomas Frisell
Feb 28, 2020·Clinical Neuropharmacology·Hussein AlgahtaniIbraheem Meftah
Aug 29, 2017·Expert Opinion on Pharmacotherapy·Katja ThomasTjalf Ziemssen

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01281657
NCT00662649

Software Mentioned

FREEDOMS
TRANSFORMS

Related Concepts

Related Feeds

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.